Masimo Corporation (NASDAQ:MASI) Receives Consensus Rating of “Hold” from Analysts

Shares of Masimo Corporation (NASDAQ:MASI) have earned a consensus recommendation of “Hold” from the eight brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $189.40.

Several equities research analysts recently commented on the stock. Wells Fargo & Company reiterated an “overweight” rating and set a $190.00 target price on shares of Masimo in a research report on Friday, December 5th. BTIG Research lifted their price target on shares of Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Monday, December 1st. Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Bank of America initiated coverage on Masimo in a report on Monday, November 17th. They set a “neutral” rating and a $162.00 target price on the stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Masimo by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,810,011 shares of the medical equipment provider’s stock valued at $709,717,000 after purchasing an additional 171,876 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Masimo by 6.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,619,960 shares of the medical equipment provider’s stock valued at $386,575,000 after acquiring an additional 149,567 shares during the last quarter. State Street Corp boosted its position in Masimo by 0.7% during the second quarter. State Street Corp now owns 1,486,394 shares of the medical equipment provider’s stock valued at $250,041,000 after acquiring an additional 10,403 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in Masimo by 20.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,419,250 shares of the medical equipment provider’s stock worth $209,410,000 after acquiring an additional 238,047 shares during the period. Finally, Alyeska Investment Group L.P. raised its position in shares of Masimo by 21.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,381,085 shares of the medical equipment provider’s stock worth $203,779,000 after acquiring an additional 246,595 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Stock Performance

Shares of Masimo stock opened at $138.92 on Friday. The company’s 50 day moving average price is $140.07 and its two-hundred day moving average price is $147.22. The firm has a market capitalization of $7.46 billion, a P/E ratio of -13.18, a P/E/G ratio of 1.42 and a beta of 1.26. Masimo has a fifty-two week low of $125.94 and a fifty-two week high of $194.88. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. The company had revenue of $617.00 million for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. On average, equities analysts forecast that Masimo will post 4.1 earnings per share for the current fiscal year.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.